{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T10:22:47Z","timestamp":1783506167268,"version":"3.55.0"},"reference-count":46,"publisher":"MDPI AG","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,9,1]]},"abstract":"<jats:title\/>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Efinaconazole 10% solution is a new triazole antifungal agent developed for the topical treatment of onychomycosis. This article reviews the pooled results of the two pivotal clinical trials of this drug that have been performed in the United States, Canada, and Japan.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The two studies of 1,655 patients were both double-blind, vehicle-controlled, parallel-group, randomized, multicenter studies designed to determine the efficacy and safety of efinaconazole 10% solution in the treatment of mild-to-moderate onychomycosis of the toenails caused by dermatophytes. Treatment was provided once daily for 48 weeks, and the primary end point was at week 52.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The combined results show a 56% mycologic cure rate compared with 17% for vehicle at week 52. Clinical treatment success was achieved in 43% of patients treated with efinaconazole 10% solution at follow-up (week 52). Clinical treatment success was achieved in 47% of patients. As expected for a topical agent, the use of efinaconazole 10% solution was found to be safe, with mild, transient irritation at the site of application reported as the most common adverse event.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The efficacy and safety profile of efinaconazole 10% solution suggests that it may represent an important advance in the topical treatment of onychomycosis. Further studies will help us better understand the role of this agent for the treatment of this widespread podiatric medical condition.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.7547\/0003-0538-104.5.479","type":"journal-article","created":{"date-parts":[[2014,10,2]],"date-time":"2014-10-02T14:13:50Z","timestamp":1412259230000},"page":"479-485","source":"Crossref","is-referenced-by-count":2,"title":["Efinaconazole 10% Solution in the Treatment of Onychomycosis of the Toenails"],"prefix":"10.3390","volume":"104","author":[{"given":"Warren S.","family":"Joseph","sequence":"first","affiliation":[{"name":"Roxborough Memorial Hospital, Philadelphia, PA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracey C.","family":"Vlahovic","sequence":"first","affiliation":[{"name":"Temple University School of Podiatric Medicine, Philadelphia, PA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radhakrishnan","family":"Pillai","sequence":"first","affiliation":[{"name":"Valeant Pharmaceuticals, Petaluma, CA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason T.","family":"Olin","sequence":"first","affiliation":[{"name":"Valeant Pharmaceuticals, Petaluma, CA."},{"name":"Valeant Pharmaceuticals North America LLC, Bridgewater, NJ."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","reference":[{"key":"ref341","doi-asserted-by":"crossref","first-page":"285","DOI":"10.2165\/00003495-199958020-00005","article-title":"Management of onychomycoses","volume":"58","author":"Niewerth","year":"1999","journal-title":"Drugs"},{"key":"ref441","first-page":"186","article-title":"Efinaconazole solution in the treatment of toenail onychomycosis: a phase 2 multicenter, randomized, double-blind study","volume":"12","author":"Tschen","year":"2013","journal-title":"J Drugs Dermatol"},{"key":"ref331","doi-asserted-by":"crossref","first-page":"19","DOI":"10.2165\/00128071-200001010-00002","article-title":"Onychomycosis: treatment, quality of life, and economic issues","volume":"1","author":"Elewski","year":"2000","journal-title":"Am J Clin Dermatol"},{"key":"ref461","doi-asserted-by":"crossref","first-page":"495","DOI":"10.7547\/87507315-90-10-495","article-title":"Ciclopirox 8% nail lacquer in the treatment of onychomycosis of the toenails in the United States","volume":"90","author":"Gupta","year":"2000","journal-title":"JAPMA"},{"key":"ref31","first-page":"151","article-title":"Onychomycosis","author":"Elewski","year":"1997","journal-title":"Nails: Diagnosis, Treatment, Surgery"},{"key":"ref451","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.jaad.2012.10.013","article-title":"Efinaconazole 10% solution in the treatment of toenail onychomycosis: two phase III multicenter, randomized, double-blind studies","volume":"68","author":"Elewski","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"ref71","doi-asserted-by":"crossref","first-page":"19","DOI":"10.2165\/00128071-200001010-00002","article-title":"Onychomycosis: treatment, quality of life, and economic issues","volume":"1","author":"Elewski","year":"2000","journal-title":"Am J Clin Dermatol"},{"key":"ref131","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/j.1468-3083.2004.00988.x","article-title":"Topical antifungal drugs for the treatment of onychomycosis: an overview of current strategies for monotherapy and combination therapy","volume":"19","author":"Baran","year":"2005","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref301","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/S0255-0857(21)01924-1","article-title":"Onychomycosis: epidemiology, diagnosis and management","volume":"26","author":"Kaur","year":"2008","journal-title":"Indian J Med Microbiol"},{"key":"ref401","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/j.1468-3083.2005.01284.x","article-title":"Treatment options: development of consensus guidelines","volume":"19","author":"Lecha","year":"2005","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref101","first-page":"1","article-title":"Onychomycosis disease management","volume":"4","author":"Salgo","year":"2003","journal-title":"Med Crossfire J Debates Peer Exchange Insights Med"},{"key":"ref371","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1046\/j.1365-2133.1999.00007.x","article-title":"Onychomycosis: current and future challenges","volume":"141","author":"Roberts","year":"1999","journal-title":"Br J Dermatol"},{"key":"ref281","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1016\/S0190-9622(99)70397-X","article-title":"Onychomycosis: therapeutic update","volume":"40","author":"Scher","year":"1999","journal-title":"J Am Acad Dermatol"},{"key":"ref181","first-page":"186","article-title":"Efinaconazole solution in the treatment of toenail onychomycosis: a phase 2 multicenter, randomized, double-blind study","volume":"12","author":"Tschen","year":"2013","journal-title":"J Drugs Dermatol"},{"key":"ref201","doi-asserted-by":"crossref","first-page":"495","DOI":"10.7547\/87507315-90-10-495","article-title":"Ciclopirox 8% nail lacquer in the treatment of onychomycosis of the toenails in the United States","volume":"90","author":"Gupta","year":"2000","journal-title":"JAPMA"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"191","DOI":"10.3810\/pgm.1998.02.359","article-title":"Common dermatophyte infections: a simple diagnostic test and current management","volume":"103","author":"Crissey","year":"1998","journal-title":"Postgrad Med"},{"key":"ref91","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S0190-9622(99)70047-2","article-title":"The impact of onychomycosis on quality of life: development of an international onychomycosis-specific questionnaire to measure patient quality of life","volume":"1","author":"Drake","year":"1999","journal-title":"J Am Acad Dermatol"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1016\/S0190-9622(99)70397-X","article-title":"Onychomycosis: therapeutic update","volume":"40","author":"Scher","year":"1999","journal-title":"J Am Acad Dermatol"},{"key":"ref321","doi-asserted-by":"crossref","first-page":"191","DOI":"10.3810\/pgm.1998.02.359","article-title":"Common dermatophyte infections: a simple diagnostic test and current management","volume":"103","author":"Crissey","year":"1998","journal-title":"Postgrad Med"},{"key":"ref191","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.jaad.2012.10.013","article-title":"Efinaconazole 10% solution in the treatment of toenail onychomycosis: two phase III multicenter, randomized, double-blind studies","volume":"68","author":"Elewski","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"ref491","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1111\/j.1468-3083.2011.04373.x","article-title":"Efficacy, safety and tolerability of topical terbinafine nail solution in patients with mild-to-moderate toenail onychomycosis: results from three randomized studies using double-blind vehicle-controlled and open-label active-controlled designs","volume":"27","author":"Elewski","year":"2013","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref501","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1001\/archderm.134.12.1551","article-title":"How often does oral treatment of toenail onychomycosis produce a disease-free nail? an analysis of published data","volume":"134","author":"Epstein","year":"1998","journal-title":"Arch Dermatol"},{"key":"ref411","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0378-5173(01)00989-9","article-title":"Drug delivery to the nail following topical application","volume":"236","author":"Murdan","year":"2002","journal-title":"Int J Pharm"},{"key":"ref391","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/j.1468-3083.2004.00988.x","article-title":"Topical antifungal drugs for the treatment of onychomycosis: an overview of current strategies for monotherapy and combination therapy","volume":"19","author":"Baran","year":"2005","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref111","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1046\/j.1365-2133.1999.00007.x","article-title":"Onychomycosis: current and future challenges","volume":"141","author":"Roberts","year":"1999","journal-title":"Br J Dermatol"},{"key":"ref171","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1128\/AAC.02063-12","article-title":"Mechanism of antifungal action of efinaconazole, a novel triazole agent","volume":"57","author":"Tasumi","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"ref81","doi-asserted-by":"crossref","first-page":"285","DOI":"10.2165\/00003495-199958020-00005","article-title":"Management of onychomycoses","volume":"58","author":"Niewerth","year":"1999","journal-title":"Drugs"},{"key":"ref231","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1111\/j.1468-3083.2011.04373.x","article-title":"Efficacy, safety and tolerability of topical terbinafine nail solution in patients with mild-to-moderate toenail onychomycosis: results from three randomized studies using double-blind vehicle-controlled and open-label active-controlled designs","volume":"27","author":"Elewski","year":"2013","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref241","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1001\/archderm.134.12.1551","article-title":"How often does oral treatment of toenail onychomycosis produce a disease-free nail? an analysis of published data","volume":"134","author":"Epstein","year":"1998","journal-title":"Arch Dermatol"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1067\/mjd.2000.104794","article-title":"Prevalence and epidemiology of onychomycosis in patients visiting physicians' offices: a multicenter Canadian survey of 15,000 patients","volume":"43","author":"Gupta","year":"2000","journal-title":"J Am Acad Dermatol"},{"key":"ref251","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1046\/j.1365-2133.1999.00008.x","article-title":"LION Study: efficacy and tolerability of continuous terbinafine (Lamisil) compared to intermittent itraconazole in the treatment of toenail onychomycosis: Lamisil vs itraconazole in onychomycosis","volume":"141","author":"Sigurgeirsson","year":"1999","journal-title":"Br J Dermatol"},{"key":"ref291","first-page":"151","article-title":"Onychomycosis","author":"Elewski","year":"1997","journal-title":"Nails: Diagnosis, Treatment, Surgery"},{"key":"ref01","first-page":"11","article-title":"Advances in the diagnosis and treatment of onychomycosis","volume":"34","author":"Scher","year":"1998","journal-title":"Hosp Med"},{"key":"ref431","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1128\/AAC.02063-12","article-title":"Mechanism of antifungal action of efinaconazole, a novel triazole agent","volume":"57","author":"Tasumi","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"ref261","first-page":"11","article-title":"Advances in the diagnosis and treatment of onychomycosis","volume":"34","author":"Scher","year":"1998","journal-title":"Hosp Med"},{"key":"ref271","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1067\/mjd.2000.104794","article-title":"Prevalence and epidemiology of onychomycosis in patients visiting physicians' offices: a multicenter Canadian survey of 15,000 patients","volume":"43","author":"Gupta","year":"2000","journal-title":"J Am Acad Dermatol"},{"key":"ref361","first-page":"1","article-title":"Onychomycosis disease management","volume":"4","author":"Salgo","year":"2003","journal-title":"Med Crossfire J Debates Peer Exchange Insights Med"},{"key":"ref161","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1128\/AAC.02056-12","article-title":"Comparison of in vitro antifungal activities of efinaconazole and currently available antifungal agents against a variety of pathogenic fungi associated with onychomycosis","volume":"57","author":"Jo Siu","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"ref511","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1046\/j.1365-2133.1999.00008.x","article-title":"LION Study: efficacy and tolerability of continuous terbinafine (Lamisil) compared to intermittent itraconazole in the treatment of toenail onychomycosis: Lamisil vs itraconazole in onychomycosis","volume":"141","author":"Sigurgeirsson","year":"1999","journal-title":"Br J Dermatol"},{"key":"ref421","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1128\/AAC.02056-12","article-title":"Comparison of in vitro antifungal activities of efinaconazole and currently available antifungal agents against a variety of pathogenic fungi associated with onychomycosis","volume":"57","author":"Jo Siu","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"ref311","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1111\/j.1439-0507.2006.01351.x","article-title":"Onychomycosis","volume":"50","author":"Seebacher","year":"2007","journal-title":"Mycoses"},{"key":"ref351","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S0190-9622(99)70047-2","article-title":"The impact of onychomycosis on quality of life: development of an international onychomycosis-specific questionnaire to measure patient quality of life","volume":"1","author":"Drake","year":"1999","journal-title":"J Am Acad Dermatol"},{"key":"ref141","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/j.1468-3083.2005.01284.x","article-title":"Treatment options: development of consensus guidelines","volume":"19","author":"Lecha","year":"2005","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/S0255-0857(21)01924-1","article-title":"Onychomycosis: epidemiology, diagnosis and management","volume":"26","author":"Kaur","year":"2008","journal-title":"Indian J Med Microbiol"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1111\/j.1439-0507.2006.01351.x","article-title":"Onychomycosis","volume":"50","author":"Seebacher","year":"2007","journal-title":"Mycoses"},{"key":"ref151","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0378-5173(01)00989-9","article-title":"Drug delivery to the nail following topical application","volume":"236","author":"Murdan","year":"2002","journal-title":"Int J Pharm"}],"container-title":["Journal of the American Podiatric Medical Association"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/meridian.allenpress.com\/japma\/article-pdf\/104\/5\/479\/1605386\/0003-0538-104_5_479.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/meridian.allenpress.com\/japma\/article-pdf\/104\/5\/479\/1605386\/0003-0538-104_5_479.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T10:12:48Z","timestamp":1783505568000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1930-8264\/104\/5\/479"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9,1]]},"references-count":46,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2014,9,1]]}},"URL":"https:\/\/doi.org\/10.7547\/0003-0538-104.5.479","relation":{},"ISSN":["8750-7315","1930-8264"],"issn-type":[{"value":"8750-7315","type":"print"},{"value":"1930-8264","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,9,1]]}}}